Nivolumab for advanced non-small cell lung cancer: an immunologically-mediated tumor checkout.
نویسندگان
چکیده
Department of Preventive Medicine Interdisciplinary, Iasi, Romania; Marius Nasta Institute, Bucuresti, Romania, Faculty of Medicine, University of Medicine Oradea, Bucuresti, Romania Correspondence to: Sabina Antoniu, MD, PhD. Lecturer, Department of Preventive Medicine Interdisciplinary, Medicine-Palliative Care Nursing, University of Medicine and Pharmacy, “Gr.T.Popa” Iasi, Romania, 16 Universitatii Str, Iasi 700115, Romania. Email: [email protected].
منابع مشابه
Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab
Nivolumab prolonged disease control in a patient with advanced squamous lung cancer that was refractory to multiple treatments. The rapid eradication of cancer after the administration of nivolumab caused hemoptysis and repeated infection. Six months after immunotherapy, mediastinal lymph node metastasis developed and afatinib effectively relieved dysphonia associated with nerve paralysis.
متن کاملComparison of PET/CT and CT-based tumor delineation and its effects on the radiation treatment planning for non-small cell lung cancer
Introduction: Tumor volume delineation is the most important step in the radiation treatment planning. In this study the impact of PET/CT data on the tumor delineation precision of non-small cell lung cancer (NSCLC) was investigated. Methods: PET/CT images of 20 patients with primary NSCLC were obtained and imported to the treatment planning system for im...
متن کاملProfile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer
Until recently, the prognosis and treatment of patients with advanced-stage squamous cell lung cancers have been limited. An improvement in the understanding of the role of the immune system in tumor immunosurveillance has led to the development of the programmed death-1 (PD-1) immune checkpoint inhibitor nivolumab (Opdivo). Nivolumab is the first PD-1 inhibitor approved for the treatment of ad...
متن کاملPeritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab
Nivolumab, a monoclonal antibody to programmed cell death protein-1 (PD-1), has revolutionised the management of patients with advanced non-small cell lung cancer (NSCLC). Treatment with nivolumab is associated with toxicities known as immune-related adverse events. Although pneumonitis is a potentially serious event, little is known of its clinical and radiographic features. We here report a c...
متن کاملConcurrent chemoradiotherapy in locally advanced non-small cell lung cancer: a retrospective analysis of the correlation between radiotherapy-related factors and tumor response
Background: To determine which radiotherapy parameters are associated with the tumor response of locally advanced non-small cell lung cancer (NSCLC) patients undergoing concurrent chemoradiotherapy. Materials and Methods: Thirty one patients with IIIA/IIIB NSCLC underwent chemoradiotherapy with a median dose of 63 Gy. On our actual treatments, we made radiotherapy planning to cover the planning...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Annals of translational medicine
دوره 4 10 شماره
صفحات -
تاریخ انتشار 2016